There are also many potent and more bioavailable EZH2 catalytic inhibitors currently undergoing phase 1/2/3 clinical trials, alone or in combination with other drugs, for the treatment of several solid tumors, mainly lymphoma, prostate cancer, and small cell lung cancer (Table 3). Here, EZH2 is linked to lymphoma.